⚡ V-Series Protocol
Accelerated tissue repair, minimized downtime
Every component is individually sourced, third-party verified, and dispensed within physician supervision. Tap any compound for its full clinical reference.
A regenerative protocol for patients managing chronic tendinopathy, post-surgical recovery, or refractory inflammatory conditions. Three synergistic peptides target distinct phases of tissue repair - vascular scaffolding, cellular proliferation, and matrix reorganization - to restore structural integrity that monotherapy cannot achieve alone. For patients who have come across pre-compounded tissue-repair blends in the market (combinations of BPC-157, TB-500 and GHK-Cu sold direct-to-consumer), V-01 is the physician-supervised, biomarker-monitored equivalent - the same regenerative building blocks, allocated and monitored within a clinical workflow rather than self-administered from a vial.
CLINICAL INDICATION: Post-surgical rehabilitation, chronic tendinopathy, refractory soft-tissue injury
Systemic regenerative protocol targeting the tendon-to-bone interface via BPC-157's nitric oxide pathway activation, TB-500's thymosin-driven angiogenesis, and GHK-Cu's collagen matrix remodeling. Clinically indicated for post-surgical rehabilitation, chronic tendinopathy, and refractory inflammatory conditions.
Standard recovery protocols treat inflammation. V-01 targets regeneration. By combining three agents that each address distinct phases of tissue repair - vascular scaffolding (TB-500), cellular proliferation (BPC-157), and extracellular matrix reorganization (GHK-Cu) - the protocol enables structural recalibration at the periosteum-tendon junction.
| What's in the box | Specification | Per month |
|---|---|---|
| GLOW (GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg) | 70mg total per vial · approximately 2 vials in this order for typical intermittent protocols | 2× |
Tissue repair / anti-inflammatory - BPC-157, TB-500, KPV, Thymosin, V-01, V-05
These protocols support healing of tendon, ligament, gut, and soft tissue, and calm systemic inflammation. Monitoring tracks inflammation coming down and confirms the body is recovering rather than being strained.
Incremental approach. Vivre uses conservative, course-based dosing - often a defined repair window rather than indefinite use. Markers and imaging confirm progress before extending.
Educational only - not medical advice or a dosing instruction. Your physician orders the tests, sets your dose, interprets results, and decides if a protocol is right for you. See the Informed Consent & Disclaimer for full terms.
PRISMA-compliant systematic review (36 studies, 1993–2025) summarising the BPC-157 evidence base. The authors documented BPC-157's mechanistic profile (growth hormone receptor enhancement, angiogenesis modulation, anti-inflammatory pathways) across preclinical IBD, GI ulcer, NSAID-induced injury, fistula, and anastomotic models. Critically, the review states: "No clinical safety data is available to date" - i.e. despite extensive preclinical activity, controlled human safety and efficacy data remain absent in the modern peer-reviewed literature.
View on publisher ↗Early Croatian Phase I/II clinical trials (PL10, PL14736) explored BPC-157 in mild-to-moderate ulcerative colitis, reporting safety and tolerability signals in small cohorts. Important caveats: these trials were conducted primarily by BPC-157's discoverers and have not been independently replicated in Western peer-reviewed RCTs at scale; detailed trial reports have not appeared in major Western journals despite frequent reference in subsequent reviews. The 2024 Sikiric et al. review summarises three decades of work but is from the originating group. Independent confirmatory trials remain absent.
View on publisher ↗In-vitro study on isolated Achilles tendon fibroblasts. BPC-157 produced time- and dose-dependent upregulation of Growth Hormone Receptor expression at the mRNA and protein level, with increased fibroblast proliferation markers. Mechanistic and preclinical; does not constitute evidence of efficacy in human tissue repair.
View on publisher ↗Preclinical study mapping cellular pathways. Identified BPC-157 activity on the FAK–paxillin migration pathway, with enhanced cell outgrowth and survival in tendon-explant models. Cellular/animal level; human controlled trial evidence remains absent.
View on publisher ↗Comprehensive narrative review of BPC-157 wound-healing data across skin wounds, burns, diabetic ulcers, alkali burns, and a distinctive body of fistula-healing work (colocutaneous, gastrocutaneous, esophagocutaneous, duodenocutaneous, vesicovaginal, rectovaginal). Documents the angiogenic mechanism - BPC-157 upregulates VEGF-a and promotes endothelial proliferation and vascular tube formation, with an angiogenic effect exceeding standard agents in the sponge assay. Two important caveats: (1) the evidence is almost entirely animal (rat/mouse, some pig) - not human outcome data; (2) it is a review by the originating Zagreb group, and most primary citations are that group's own work, so it has not been independently replicated at scale. Note also that the same pro-angiogenic/VEGF action that drives healing is the basis for the theoretical oncologic caution discussed for any angiogenic compound.
View on publisher ↗Review proposing BPC-157 as a candidate for cancer cachexia (cancer-related muscle/fat wasting). In a C-26 colon-adenocarcinoma mouse model the peptide antagonised TNF-α and IL-6, cytokines central to cachexia. Preclinical and pre-clinical-trial - a proposal, not an outcome study - and from the originating (Sikiric) group.
View on publisher ↗In vitro: BPC-157 (2–10 ng) reduced human melanoma cell S-phase fraction by up to ~55% and decreased ERK phosphorylation - i.e. it acted as an antimitogenic agent INHIBITING the VEGF-MAPK proliferative signal in melanoma cells. A conference abstract (no full text), from the originating group; counterintuitive against the “BPC promotes angiogenesis” healing literature, which is why both directions matter.
View on publisher ↗A 2025 review in which the originating group directly addresses the tumour-risk speculation: it argues BPC-157 CONTROLS/MODULATES angiogenesis rather than driving tumorigenesis (e.g. it opposes corneal neovascularisation - “angiogenic privilege”), reports anti-tumour potential in vitro and in vivo per Folkman’s concept, and notes LD1 not achieved with no reported adverse effects. Important read: this is a defence authored by the compound’s originating group, so it answers but does not independently close the theoretical tumour-risk question.
View on publisher ↗Preclinical · Mouse Model. Landmark study showing that Thymosin β4 (the parent peptide of TB-500) administered to mouse hearts after coronary artery ligation activated integrin-linked kinase, promoted cardiomyocyte migration and survival, and improved cardiac function. Established TB4 as a candidate for cardiac repair research. The findings are preclinical (mouse); they catalysed subsequent human-cardiac TB4 research that has not yet produced definitive outcome trials.
View on publisher ↗Preclinical · Mouse Model. Demonstrated that systemic Thymosin β4 mobilises adult epicardial progenitor cells and induces neovascularization in mouse models of cardiac injury. Showed stimulated migration of resident endothelial cells, accelerated localised angiogenesis, reduced myocardial scar/fibrosis, and preserved cardiac ejection fraction. Together with Bock-Marquette 2004, this paper established the strongest preclinical case for TB4 as a cardiac-repair candidate. Direct human-cardiac RCT translation has not occurred; ophthalmic and dermal-wound human trials of TB4 (not the TB-500 fragment) exist.
View on publisher ↗In Vitro & Mechanistic Review. Mechanistic review and supporting laboratory data characterising Thymosin β4 as a G-actin sequestering molecule. Identified roles in endothelial cell migration and angiogenesis in wound-healing models. Findings remain primarily preclinical; controlled human trial evidence specific to the TB-500 fragment is limited.
View on publisher ↗Randomized, controlled, multi-center trial in patients with chronic non-healing diabetic foot ulcers. Topical GHK-Cu hydrogel achieved 87.5–88% complete wound closure compared with 30–34% in the standard-care control arm. Median time to complete closure was approximately 6.2 weeks for the GHK-Cu group versus more than 11 weeks for control. Localized infection rates were also significantly reduced. This remains one of the strongest human RCT data points for any peptide in the regenerative category.
View on publisher ↗Landmark in vitro study in human dermal fibroblast cultures. Demonstrated that micromolar GHK-Cu drives dose-dependent synthesis of Type I and Type III collagen, elastin, and glycosaminoglycans, and balances matrix metalloproteinase (MMP) and TIMP activity to favour clean tissue remodelling over fibrotic scarring. The mechanistic basis for GHK-Cu’s use in dermal-architecture protocols.
View on publisher ↗Broad Institute Connectivity Map (cMap) computational analysis quantified that GHK-Cu modulates expression of approximately 4,192 human genes, shifting tissue toward a younger homeostatic profile. Upregulates antioxidant systems, neurotrophic factors, and metabolic clearance pathways; downregulates pro-inflammatory networks. The genomic-systems basis for why GHK-Cu has effects across multiple tissue beds.
View on publisher ↗Review of the GHK-Cu literature including gene-expression profiling work showing modulation of multiple tissue-repair-related genes, with effects on collagen synthesis, matrix metalloproteinase regulation, and inflammatory signalling. Strongest evidence is in dermal/topical applications; systemic use is less characterised in controlled trials.
View on publisher ↗In vitro and ex vivo dermal study (human keratinocytes). Demonstrated that GHK-Cu maintains the stemness of basal keratinocytes and integrin expressions, mobilising intrinsic progenitor cell lines to migrate toward sites of acute structural degradation. Provides the cellular basis for GHK-Cu’s role in dermal renewal beyond fibroblast-mediated matrix synthesis.
View on publisher ↗Mechanistic review documenting GHK’s role as a non-toxic copper chaperone delivering Cu(II) into cells without triggering radical-induced lipid peroxidation. Cytochrome c Oxidase (Complex IV) of the mitochondrial electron transport chain requires copper at its catalytic centres, so adequate copper delivery is upstream of ATP synthesis. Genomic profiling confirmed upregulation of PGC-1α pathway genes (mitochondrial biogenesis). The often-quoted "67% ATP increase" originates from localised in vitro stress-condition data and should be framed as "restoration of defective ATP production under cellular stress" rather than a baseline boost - Vivre presents it this way honestly.
View on publisher ↗Preclinical · Animal Models. In rat coronary-ligation experiments, pre-treatment with GHK-Cu reduced infarct size and preserved cardiac function via upregulation of bFGF and VEGF (angiogenesis). In rodent diabetic nephropathy models, GHK-Cu downregulated TGF-β (the primary fibrosis driver), reducing mesangial expansion, basement membrane thickening, and extracellular matrix accumulation in the renal filtering apparatus. Note: these are animal-model data and have not been translated to human cardiology or nephrology RCTs - Vivre cites them as mechanistic support for the tissue-remodelling case, not as human clinical efficacy.
View on publisher ↗Preclinical · Rodent and In Vitro. Genomic data verify that GHK-Cu downregulates the amyloid precursor protein (APP) gene and upregulates neurotrophic pathways (NGF and BDNF). Animal-model evidence indicates blood-brain-barrier permeability and neuroprotective effects against beta-amyloid and oxidative-stress insults. The frequently-quoted "300% NGF increase" originates from rodent / in-vitro data and is presented here as preclinical signal, not as human cognitive-clinical evidence - which does not yet exist in controlled RCT form for GHK-Cu.
View on publisher ↗Preclinical · In Vitro + Mouse Alopecia Model. The novel contribution of the paper is a bio-based ionic liquid microemulsion (CaT-ME, made from L-carnitine and tartaric acid) as a topical delivery vehicle - not GHK-Cu efficacy per se. Loaded with GHK-Cu, the system improved porcine-skin permeation 3.18× vs PBS in vitro, and in a C57BL/6 mouse alopecia model, GHK-Cu/CaT-ME entered the anagen (growth) phase at day 6 versus day 9 for 5% topical minoxidil - a head-to-head win against the FDA-approved comparator in a mouse model. Mechanism work documented upregulation of VEGF and HGF (follicular angiogenic factors), CD31 (vascular endothelium), Ki67 (proliferation), β-catenin and p-GSK3β (Wnt pathway activation), and Ldha (hair follicle stem cell activation enzyme). The paper reinforces three mechanisms that anchor GHK-Cu's hair-growth thesis: fibroblast-stimulated VEGF, TGF-β suppression preventing premature anagen→catagen, and dermal papilla cell proliferation. Important methodology framing: preclinical (mouse + ex vivo porcine skin) only - no human RCT. The route tested is topical microemulsion, not the injectable route Vivre offers - the shared element is the GHK-Cu mechanism, not the delivery vehicle. Two co-author affiliations (Shenzhen Shinehigh Innovation Technology, Harbin Voolga Technology) have commercial interests in the technology, and the GHK-Cu raw material was supplied by a related Shenzhen entity. The authors declare no conflict of interest per ICMJE rules, but the originating-group + commercial-affiliation pattern is flagged here per Vivre's standard discipline (same approach applied to Epithalon and other single-group preclinical work).
View on publisher ↗| Additional Marker | Why It's Added | Cadence |
|---|---|---|
| hs-CRP | Baseline inflammation status and treatment response signal | Baseline + wk 6, 12 |
| IL-6 (where available) | More sensitive cytokine-level inflammation readout when local burden is high | Wk 6, 12 |
| Subjective recovery score (validated PROM) | Patient-reported pain, stiffness, perceived recovery quality | Bi-weekly |
| Local tissue response (where applicable) | Standardised photo or clinical assessment for dermal involvement | Wk 4, 8, 12 |
The Audit is complimentary for the Batch 001 cohort. Your physician will review your data, confirm protocol suitability, and initiate the V-01 allocation if appropriate.
Are you 18 years of age or older?